[Proceedings: Review of the cardiovascular pharmacology of perhexiline].
D000818:Animals; D000889:Anti-Arrhythmia Agents; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D004734:Energy Metabolism; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006325:Heart Atria / Q000187:drug effects; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D009206:Myocardium / Q000378:metabolism; D005996:Nitroglycerin / Q000494:pharmacology; D010101:Oxygen Consumption; D010480:Perhexiline / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011950:Receptors, Cholinergic / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D010880:Piperidines; D011950:Receptors, Cholinergic; D014665:Vasodilator Agents; D005996:Nitroglycerin; D010480:Perhexiline